TY - JOUR
T1 - Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan
AU - Hasegawa, Seiki
AU - Shintani, Yasushi
AU - Takuwa, Teruhisa
AU - Aoe, Keisuke
AU - Kato, Katsuya
AU - Fujimoto, Nobukazu
AU - Hida, Yasuhiro
AU - Morise, Masahiro
AU - Moriya, Yasumitsu
AU - Morohoshi, Takao
AU - Suzuki, Hidemi
AU - Chida, Masayuki
AU - Endo, Shunsuke
AU - Kadokura, Mitsutaka
AU - Okumura, Meinoshin
AU - Hattori, Satoshi
AU - Date, Hiroshi
AU - Yoshino, Ichiro
N1 - Publisher Copyright:
© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
PY - 2024/2
Y1 - 2024/2
N2 - Due to the scarcity of large-sized prospective databases, the Japanese Joint Committee for Lung Cancer Registry conducted a nationwide prospective registry for newly diagnosed and untreated pleural mesothelioma. All new cases diagnosed pathologically as any subtype of pleural mesothelioma in Japan during the period between April 1, 2017, to March 31, 2019, were included before treatment. Data on survival were collected in April 2021. The eligible 346 patients (285 men [82.3%]; 61 women [17.7%]; median age, 71.0 years [range, 44–88]) were included for analysis. Among these patients, 138 (39.9%) underwent surgery, 164 (47.4%) underwent non-surgical therapy, and the remaining 44 (12.7%) underwent best supportive care. The median overall survival for all 346 patients was 19.0 months. Survival rates at 1, 2, and 3 years for all patients were, 62.8%, 42.3%, and 26.5%, respectively. Median overall survival was significantly different among patients undergoing surgery, non-surgical treatment, and best supportive care (32.2 months vs. 14.0 months vs. 3.8 months, p < 0.001). The median overall survival of patients undergoing pleurectomy/decortication and extrapleural pneumonectomy was 41.8 months and 25.0 months, respectively. Macroscopic complete resection resulted in longer overall survival than R2 resection and partial pleurectomy/exploratory thoracotomy (41.8 months vs. 32.2 months vs. 16.8 months, p < 0.001). Tumor shape, maximum tumor thickness, and sum of three level thickness were significant prognostic factors. The data in the prospective database would serve as a valuable reference for clinical practice and further studies for pleural mesothelioma.
AB - Due to the scarcity of large-sized prospective databases, the Japanese Joint Committee for Lung Cancer Registry conducted a nationwide prospective registry for newly diagnosed and untreated pleural mesothelioma. All new cases diagnosed pathologically as any subtype of pleural mesothelioma in Japan during the period between April 1, 2017, to March 31, 2019, were included before treatment. Data on survival were collected in April 2021. The eligible 346 patients (285 men [82.3%]; 61 women [17.7%]; median age, 71.0 years [range, 44–88]) were included for analysis. Among these patients, 138 (39.9%) underwent surgery, 164 (47.4%) underwent non-surgical therapy, and the remaining 44 (12.7%) underwent best supportive care. The median overall survival for all 346 patients was 19.0 months. Survival rates at 1, 2, and 3 years for all patients were, 62.8%, 42.3%, and 26.5%, respectively. Median overall survival was significantly different among patients undergoing surgery, non-surgical treatment, and best supportive care (32.2 months vs. 14.0 months vs. 3.8 months, p < 0.001). The median overall survival of patients undergoing pleurectomy/decortication and extrapleural pneumonectomy was 41.8 months and 25.0 months, respectively. Macroscopic complete resection resulted in longer overall survival than R2 resection and partial pleurectomy/exploratory thoracotomy (41.8 months vs. 32.2 months vs. 16.8 months, p < 0.001). Tumor shape, maximum tumor thickness, and sum of three level thickness were significant prognostic factors. The data in the prospective database would serve as a valuable reference for clinical practice and further studies for pleural mesothelioma.
KW - chemotherapy
KW - database
KW - pleural mesothelioma
KW - staging system
KW - surgery
UR - http://www.scopus.com/inward/record.url?scp=85178426452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178426452&partnerID=8YFLogxK
U2 - 10.1111/cas.16021
DO - 10.1111/cas.16021
M3 - Article
C2 - 38047872
AN - SCOPUS:85178426452
SN - 1347-9032
VL - 115
SP - 507
EP - 528
JO - Cancer science
JF - Cancer science
IS - 2
ER -